# High Dose Carfilzomib for Newly Diagnosed Myeloma

> **NCT02937571** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02937571
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-10-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937571, "High Dose Carfilzomib for Newly Diagnosed Myeloma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02937571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*